Thursday, October 15, 2026

Unite Group Plans £300-400M Asset Sales as Nomination Beds Drop 2,000 Units

Unite Group faces a 1,000-2,000 bed reduction in university nominations for 2026, prompting £300-400 million in disposals to rebalance its portfolio. The student accommodation REIT maintains flat dividend guidance despite rental growth of 2.4% falling at the lower end of projections, with current bookings at 68% compared to typical sales cycles.

Unite Group Plans £300-400M Asset Sales as Nomination Beds Drop 2,000 Units
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Unite Group will sell £300-400 million of student housing assets in 2026 to offset declining university nomination agreements. The UK's largest student accommodation REIT expects nominations to fall by 1,000-2,000 beds next year as universities reduce guaranteed occupancy commitments.

The company set adjusted EPS guidance at 41.5-43 pence for 2026 with dividends held flat. Rental growth on a Revenue Per Occupied Room basis reached 2.4%, landing at the bottom of the firm's 2-3% target range. Current bookings stand at 68% for the upcoming academic year, below historical pace due to universities cutting nomination allocations earlier in the sales cycle.

Unite is repositioning toward direct-let beds with higher margins. High-tariff properties now represent 67% of the portfolio, up from previous periods, with management targeting 80% over the medium term. The shift addresses margin pressure from nomination bed economics as universities negotiate harder on guaranteed occupancy deals.

Disposal yields are expected around 5.5-6% on average, creating a capital recycling opportunity. Unite plans to redeploy proceeds into higher-yielding direct-let properties and premium student housing in core university markets. The strategy aims to maintain earnings targets while reducing exposure to institutional nomination agreements that lock in lower returns.

The nomination model historically provided occupancy certainty but capped rental upside. Universities now face budget pressures and enrollment uncertainty, making multi-year bed guarantees less attractive. REITs with heavy nomination exposure must either accept compressed margins or pivot to direct student lettings that carry operational risk but higher profit potential.

Unite's disposal program tests whether capital redeployment can offset nomination headwinds fast enough to hit 2026 earnings guidance. The 12-15 month lag between asset sales and redeployment into stabilized properties creates execution risk. Success depends on finding acquisition targets yielding above the 5.5-6% disposal rate while maintaining occupancy levels in a competitive student housing market where universities now compete directly with private operators.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com